Login / Signup

Impact of Increasing PD-L1 Levels on Outcomes to PD-1/PD-L1 Inhibition in Patients With NSCLC: A Pooled Analysis of 11 Prospective Clinical Trials.

Jonathon VallejoHarpreet SinghErin LarkinsNicole DreznerBiagio RicciutiPallavi Mishra-KalyaniShenghui TangJulia A BeaverMark M Awad
Published in: The oncologist (2024)
These analyses suggest PD-L1 expression has an appreciable impact on clinical outcomes for patients with NSCLC treated with ICI. As the impact of PD-L1 expression on outcomes may vary across regions, it is critical that future trials are multiregional and enroll a diverse patient population.
Keyphrases
  • small cell lung cancer
  • clinical trial
  • advanced non small cell lung cancer
  • case report
  • type diabetes
  • current status
  • metabolic syndrome
  • skeletal muscle
  • newly diagnosed
  • open label
  • phase ii
  • tyrosine kinase